Profile data is unavailable for this security.
About the company
Captor Therapeutics SA is a Poland-based biopharmaceutical company, which specializes in the development of drugs that cause the targeted degradation of pathogenic proteins. The Company works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The Company covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.
- Revenue in PLN (TTM)7.57m
- Net income in PLN-40.71m
- Incorporated2018
- Employees91.00
- LocationCaptor Therapeutics SAul. Dunska 11WROCLAW 54-427PolandPOL
- Websitehttps://www.captortherapeutics.pl/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Poltreg SA | 0.00 | -24.56m | 124.05m | 33.00 | -- | 2.51 | -- | -- | -5.27 | -5.27 | 0.00 | 10.61 | 0.00 | 16.45 | -- | 0.00 | -25.87 | -9.02 | -29.62 | -10.18 | -- | -659.36 | -- | -854.23 | 2.65 | -- | 0.1365 | -- | -74.98 | -6.89 | -38.06 | -- | 83.47 | -- |
| Mabion SA | 14.81m | -59.30m | 132.21m | 204.00 | -- | 1.89 | -- | 8.93 | -3.67 | -3.67 | 0.9164 | 4.33 | 0.0988 | 8.10 | 27.25 | 72,602.94 | -39.56 | 0.5366 | -54.81 | 1.06 | -178.55 | 58.34 | -400.37 | 0.9643 | 0.2276 | -- | 0.04 | -- | -54.50 | -- | -115.35 | -- | 6.00 | -- |
| Molecure SA | 5.11m | -24.42m | 151.43m | 71.00 | -- | 1.69 | -- | 29.62 | -1.20 | -1.20 | 0.2493 | 4.34 | 0.0553 | -- | 7.01 | 50,119.41 | -26.42 | -3.15 | -27.53 | -3.30 | 51.48 | 93.34 | -477.67 | -15.45 | -- | -- | 0.0588 | -- | -40.47 | 278.20 | -10.27 | -- | 12.49 | -- |
| BIOTON SA | 295.81m | -2.82m | 339.16m | 363.00 | -- | 0.5728 | 9.59 | 1.15 | -0.0329 | -0.0329 | 3.45 | 6.90 | 0.3814 | 2.02 | 8.84 | 814,906.30 | -0.3638 | 0.5935 | -0.4325 | 0.7338 | 29.69 | 41.35 | -0.954 | 2.47 | 0.5186 | 1.64 | 0.0682 | 0.00 | 14.38 | 0.561 | -788.26 | -- | -26.87 | -- |
| Scope Fluidics SA | 718.00k | 54.47m | 453.06m | 132.00 | 7.15 | 3.38 | 8.02 | 631.01 | 19.99 | 19.99 | 0.2633 | 42.35 | 0.0065 | 0.9348 | 10.80 | 11,396.83 | 49.25 | 54.44 | 52.79 | 58.98 | -178.69 | -440.53 | 7,586.77 | 33,272.12 | 12.82 | -- | 0.0212 | -- | -74.61 | -- | 448.26 | -- | 5.75 | -- |
| Captor Therapeutics SA | 7.57m | -40.71m | 463.15m | 91.00 | -- | 13.86 | -- | 61.18 | -7.68 | -7.68 | 1.43 | 6.02 | 0.1387 | -- | 4.27 | 83,186.81 | -74.58 | -43.62 | -102.84 | -55.62 | 65.32 | 65.95 | -537.79 | -450.96 | -- | -- | 0.1029 | -- | 19.88 | -- | 45.56 | -- | 13.11 | -- |
| Ryvu Therapeutics SA | 69.80m | -118.69m | 593.03m | 294.00 | -- | 8.33 | -- | 8.50 | -5.13 | -5.13 | 3.02 | 3.08 | 0.212 | 12.29 | 7.31 | 237,411.60 | -36.05 | -23.64 | -48.51 | -27.84 | 70.86 | 29.35 | -170.05 | -208.85 | 2.26 | -- | 0.572 | -- | 66.38 | 83.01 | -20.98 | -- | -24.46 | -- |
| Selvita SA | 373.90m | -2.89m | 816.82m | 434.00 | -- | 2.58 | 15.47 | 2.18 | -0.1577 | -0.1577 | 20.37 | 17.23 | 0.5983 | 8.96 | 4.97 | 398,187.40 | -0.4629 | 5.76 | -0.5715 | 7.33 | 80.27 | 80.65 | -0.7737 | 8.57 | 0.8823 | 0.7538 | 0.3757 | -- | -1.73 | -- | -108.73 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Captor Therapeutics SA's reporting currency: Polish New Zloty PLN
12.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Allianz Polska PTE SAas of 31 Dec 2024 | 229.00k | 4.14% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 146.58k | 2.65% |
| Generali PTE SAas of 31 Dec 2024 | 141.49k | 2.56% |
| Allianz Polska TFI SAas of 30 Jun 2025 | 105.36k | 1.91% |
| Millennium TFI SAas of 30 Jun 2025 | 35.22k | 0.64% |
| AgioFunds TFI SAas of 30 Dec 2025 | 25.42k | 0.46% |
| Pekao TFI SAas of 31 Dec 2024 | 5.77k | 0.10% |
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 115.00 | 0.00% |
| PTE PZU SAas of 30 Jun 2025 | 0.00 | 0.00% |
| Investors TFI SAas of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2025 - 08 Jan 2026Source: FactSet Research Systems Inc.
